Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

BioAge Labs (BIOA) Cost of Revenue (2024 - 2026)

BioAge Labs' Cost of Revenue history spans 2 years, with the latest figure at $18.6 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 39.35% to $18.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $49.4 million, a 33.17% increase, with the full-year FY2025 number at $49.4 million, up 33.17% from a year prior.
  • Cost of Revenue hit $18.6 million in Q4 2025 for BioAge Labs, up from $12.2 million in the prior quarter.
  • Over the last five years, Cost of Revenue for BIOA hit a ceiling of $18.6 million in Q4 2025 and a floor of $4.6 million in Q1 2024.